Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells

Redox Biology

Volumn 13, Issue , 2017, Pages 470-476

  Park, Sangkyu ^a   Park, Jeong A ^a   Yoo, Hwanmin ^a   Park, Han Bum ^a   Lee, Younghee ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Caspase; Cleavage; HSP90; Proteasome inhibitor; ROS; VDUP1

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 10; HEAT SHOCK PROTEIN 90; PROTEASOME INHIBITOR; ACETYLCYSTEINE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CARRIER PROTEIN; GLUTATHIONE; LEUPEPTIN; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SCAVENGER; TXNIP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; ELECTRON TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LIPID METABOLISM; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; DRUG EFFECTS; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; LEUKEMIA; MCF-7 CELL LINE; METABOLISM; PROTEIN DEGRADATION;

ACETYLCYSTEINE; CARRIER PROTEINS; CASPASE 10; FREE RADICAL SCAVENGERS; GLUTATHIONE; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; LEUKEMIA; LEUPEPTINS; MCF-7 CELLS; PROTEASE INHIBITORS; PROTEOLYSIS; REACTIVE OXYGEN SPECIES;

EID: 85023594829     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.07.010     Document Type: Article

References (59)

1. Welch, W.J., How cells respond to stress. Sci. Am. 268 (1993), 56–64.
2. Neckers, L., Workman, P., Hsp90 molecular chaperone inhibitors: are we there yet?. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 18 (2012), 64–76.
3. Sharp, S., Workman, P., Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 95 (2006), 323–348.
4. Miyata, Y., Nakamoto, H., Neckers, L., The therapeutic target Hsp90 and cancer hallmarks. Curr. Pharm. Des. 19 (2013), 347–365.
5. Ferrarini, M., Heltai, S., Zocchi, M.R., Rugarli, C., Unusual expression and localization of heat-shock proteins in human tumor cells. Int. J. Cancer 51 (1992), 613–619.
6. Boltze, C., Lehnert, H., Schneider-Stock, R., Peters, B., Hoang Vu, C., Roessner, A., Withdrawal. HSP90 is a key for telomerase activation and malignant transition in pheochromocytoma. Endocrine, 23, 2004, 229.
7. Neckers, L., Mimnaugh, E., Schulte, T.W., Hsp90 as an anti-cancer target. Drug Resist. Update: Rev. Comment. Antimicrob. Anticancer Chemother. 2 (1999), 165–172.
8. Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M.E., Sugarman, S., Ma, W., Patil, S., Norton, L., et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 17 (2011), 5132–5139.
9. Dickson, M.A., Okuno, S.H., Keohan, M.L., Maki, R.G., D'Adamo, D.R., Akhurst, T.J., Antonescu, C.R., Schwartz, G.K., Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. 24 (2013), 252–257.
10. Sreedhar, A.S., Kalmar, E., Csermely, P., Shen, Y.F., Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 562 (2004), 11–15.
11. Prodromou, C., Roe, S.M., O'Brien, R., Ladbury, J.E., Piper, P.W., Pearl, L.H., Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90 (1997), 65–75.
12. Rohl, A., Rohrberg, J., Buchner, J., The chaperone Hsp90: changing partners for demanding clients. Trends Biochem. Sci. 38 (2013), 253–262.
13. Wandinger, S.K., Richter, K., Buchner, J., The Hsp90 chaperone machinery. J. Biol. Chem. 283 (2008), 18473–18477.
14. Hessling, M., Richter, K., Buchner, J., Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat. Struct. Mol. Biol. 16 (2009), 287–293.
15. Prodromou, C., Panaretou, B., Chohan, S., Siligardi, G., O'Brien, R., Ladbury, J.E., Roe, S.M., Piper, P.W., Pearl, L.H., The ATPase cycle of Hsp90 drives a molecular ‘clamp’ via transient dimerization of the N-terminal domains. EMBO J. 19 (2000), 4383–4392.
16. Richter, K., Buchner, J., Hsp90: chaperoning signal transduction. J. Cell. Physiol. 188 (2001), 281–290.
17. Zuehlke, A., Johnson, J.L., Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 93 (2010), 211–217.
18. Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., Seto, E., Bhalla, K., Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280 (2005), 26729–26734.
19. Scroggins, B.T., Robzyk, K., Wang, D., Marcu, M.G., Tsutsumi, S., Beebe, K., Cotter, R.J., Felts, S., Toft, D., Karnitz, L., Rosen, N., Neckers, L., An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25 (2007), 151–159.
20. Chen, H., Xia, Y., Fang, D., Hawke, D., Lu, Z., Caspase-10-mediated heat shock protein 90 beta cleavage promotes UVB irradiation-induced cell apoptosis. Mol. Cell. Biol. 29 (2009), 3657–3664.
21. Beck, R., Verrax, J., Gonze, T., Zappone, M., Pedrosa, R.C., Taper, H., Feron, O., Calderon, P.B., Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem. Pharmacol. 77 (2009), 375–383.
22. Beck, R., Dejeans, N., Glorieux, C., Creton, M., Delaive, E., Dieu, M., Raes, M., Leveque, P., Gallez, B., Depuydt, M., Collet, J.F., Calderon, P.B., Verrax, J., Hsp90 is cleaved by reactive oxygen species at a highly conserved N-terminal amino acid motif. PLoS One, 7, 2012, e40795.
23. Liu, S.H., Lin, C.H., Liang, F.P., Chen, P.F., Kuo, C.D., Alam, M.M., Maiti, B., Hung, S.K., Chi, C.W., Sun, C.M., Fu, S.L., Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem. Pharmacol. 87 (2014), 229–242.
24. Park, S., Park, J.A., Kim, Y.E., Song, S., Kwon, H.J., Lee, Y., Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells. Cell Stress Chaperon. 20 (2015), 149–157.
25. Inoue, M., Sato, E.F., Nishikawa, M., Park, A.M., Kira, Y., Imada, I., Utsumi, K., Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr. Med. Chem. 10 (2003), 2495–2505.
26. Hole, P.S., Darley, R.L., Tonks, A., Do reactive oxygen species play a role in myeloid leukemias?. Blood 117 (2011), 5816–5826.
27. Cai, J., Jones, D.P., Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss. J. Biol. Chem. 273 (1998), 11401–11404.
28. Dypbukt, J.M., Ankarcrona, M., Burkitt, M., Sjoholm, A., Strom, K., Orrenius, S., Nicotera, P., Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin-secreting RINm5F cells. The role of intracellular polyamines. J. Biol. Chem. 269 (1994), 30553–30560.
29. Simon, H.U., Haj-Yehia, A., Levi-Schaffer, F., Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis: Int. J. Program. Cell Death 5 (2000), 415–418.
30. Martin, K.R., Barrett, J.C., Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum. Exp. Toxicol. 21 (2002), 71–75.
31. Cairns, R.A., Harris, I.S., Mak, T.W., Regulation of cancer cell metabolism. Nat. Rev. Cancer 11 (2011), 85–95.
32. Kaimul, A.M., Nakamura, H., Masutani, H., Yodoi, J., Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic. Biol. Med. 43 (2007), 861–868.
33. Kwon, H.J., Won, Y.S., Suh, H.W., Jeon, J.H., Shao, Y., Yoon, S.R., Chung, J.W., Kim, T.D., Kim, H.M., Nam, K.H., Yoon, W.K., Kim, D.G., Kim, J.H., et al. Vitamin D3 upregulated protein 1 suppresses TNF-alpha-induced NF-kappaB activation in hepatocarcinogenesis. J. Immunol. (Baltim., Md.: 1950) 185 (2010), 3980–3989.
34. Crawford, L.J., Walker, B., Irvine, A.E., Proteasome inhibitors in cancer therapy. J. Cell Commun. Signal. 5 (2011), 101–110.
35. Lee, D.H., Goldberg, A.L., Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8 (1998), 397–403.
36. Shirley, R.B., Kaddour-Djebbar, I., Patel, D.M., Lakshmikanthan, V., Lewis, R.W., Kumar, M.V., Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells. Neoplasia (New York, N. Y.) 7 (2005), 1104–1111.
37. Han, Y.H., Moon, H.J., You, B.R., Park, W.H., The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol. Rep. 22 (2009), 215–221.
38. Kim, Y.J., Kim, D., Lee, Y., Choi, S.Y., Park, J., Lee, S.Y., Park, J.W., Kwon, H.J., Effects of nanoparticulate saponin-platinum conjugates on 2,4-dinitrofluorobenzene-induced macrophage inflammatory protein-2 gene expression via reactive oxygen species production in RAW 264.7 cells. BMB Rep. 42 (2009), 304–309.
39. Dickinson, D.A., Forman, H.J., Cellular glutathione and thiols metabolism. Biochem. Pharmacol. 64 (2002), 1019–1026.
40. Junn, E., Han, S.H., Im, J.Y., Yang, Y., Cho, E.W., Um, H.D., Kim, D.K., Lee, K.W., Han, P.L., Rhee, S.G., Choi, I., Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J. Immunol. (Baltim., Md.: 1950) 164 (2000), 6287–6295.
41. Han, Y.H., Park, W.H., The changes of reactive oxygen species and glutathione by MG132, a proteasome inhibitor affect As4.1 juxtaglomerular cell growth and death. Chem.-Biol. Interact. 184 (2010), 319–327.
42. Zhang, P., Wang, C., Gao, K., Wang, D., Mao, J., An, J., Xu, C., Wu, D., Yu, H., Liu, J.O., Yu, L., The ubiquitin ligase itch regulates apoptosis by targeting thioredoxin-interacting protein for ubiquitin-dependent degradation. J. Biol. Chem. 285 (2010), 8869–8879.
43. McIlwain, D.R., Berger, T., Mak, T.W., Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol., 7, 2015, 10.1101/cshperspect.a026716.
44. Poreba, M., Strozyk, A., Salvesen, G.S., Drag, M., Caspase substrates and inhibitors. Cold Spring Harb. Perspect. Biol., 5, 2013, a008680.
45. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl. J. Med. 348 (2003), 2609–2617.
46. Curran, M.P., McKeage, K., Bortezomib: a review of its use in patients with multiple myeloma. Drugs 69 (2009), 859–888.
47. Emanuele, S., Calvaruso, G., Lauricella, M., Giuliano, M., Bellavia, G., D'Anneo, A., Vento, R., Tesoriere, G., Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3. Int. J. Oncol. 21 (2002), 857–865.
48. Perez-Galan, P., Roue, G., Villamor, N., Montserrat, E., Campo, E., Colomer, D., The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107 (2006), 257–264.
49. Ortiz-Lazareno, P.C., Bravo-Cuellar, A., Lerma-Diaz, J.M., Jave-Suarez, L.F., Aguilar-Lemarroy, A., Dominguez-Rodriguez, J.R., Gonzalez-Ramella, O., De Celis, R., Gomez-Lomeli, P., Hernandez-Flores, G., Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss. Cancer Cell Int., 14, 2014 (13-2867-14-13).
50. Cusimano, A., Azzolina, A., Iovanna, J.L., Bachvarov, D., McCubrey, J.A., D'Alessandro, N., Montalto, G., Cervello, M., Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle (Georget., Tex.) 9 (2010), 1399–1410.
51. Peron, M., Bonvini, P., Rosolen, A., Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro. BMC Cancer, 12, 2012 (233-2407-12-233).
52. Wang, R.E., Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr. Med. Chem. 18 (2011), 4250–4264.
53. Zismanov, V., Drucker, L., Gottfried, M., Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration. Anti-Cancer Drugs 25 (2014), 998–1006.
54. Suh, H.W., Yun, S., Song, H., Jung, H., Park, Y.J., Kim, T.D., Yoon, S.R., Choi, I., TXNIP interacts with hEcd to increase p53 stability and activity. Biochem. Biophys. Res. Commun. 438 (2013), 264–269.
55. Zhou, J., Yu, Q., Chng, W.J., TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int. J. Biochem. Cell Biol. 43 (2011), 1668–1673.
56. Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H., Takagi, Y., Sono, H., Gon, Y., Yodoi, J., Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem. 274 (1999), 21645–21650.
57. Chung, J.W., Jeon, J.H., Yoon, S.R., Choi, I., Vitamin D3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases. J. Dermatol. 33 (2006), 662–669.
58. Butler, L.M., Zhou, X., Xu, W.S., Scher, H.I., Rifkind, R.A., Marks, P.A., Richon, V.M., The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 99 (2002), 11700–11705.
59. Lushchak, V.I., Glutathione homeostasis and functions: potential targets for medical interventions. J. Amino Acids, 2012, 2012, 736837.